Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Fastenal a Good Stock to Buy? The Smart Money Thinks So

Is Fastenal a good stock to buy? Earlier this week, J Michael Ancius, Director at Fastenal Company (NASDAQ:FAST) filed a Form 4 at the U.S. Securities and Exchange Commission declaring a purchase of 525 shares that he made last Friday, Oct. 11th. Out of them, 435 shares went to his direct holdings and an extra 90, to Ancius’ son (although Ancius himself states indirect ownership of them).

Fastenal Company (NASDAQ:FAST)

The company Director seems to have taken advantage of the substantial drop in the stock price that followed the dismal third quarter earnings report, released on Oct. 9th. Ancius paid $47.91 per share on Friday, and has already realized an upside of about 3%, given that the stock now trades at $48.05. Following the reported transactions, the insider directly holds 6,600*shares of common stock, valued at $317,130. In addition, he owns another 589 shares indirectly, through his son and a child custodian account.

While Ancius seems to bet on Fastenal, notwithstanding the latest earnings and revenue misses, analysts are not so confident. For instance, Allison Poliniak-Cusic, a Wells Fargo analyst, recently recommended staying away from the stock at the time. Actually, most analysts are trending toward a hold recommendation.

Nevertheless, about 26 of the hedge funds that we track hold a position at Fastenal. The largest “hedgie” bull by a wide margin is Timothy S. Peterson‘s Regiment Capital, which holds a $68,383,000 (approx.) stake in the company (this account for almost 20% of its equity portfolio). The other very large institutional supporter is Jim Simons‘ Renaissance Technologies, which holds $34,500,000 in stock.

  FAST Ind. Avg.
Operating Margin % TTM 21.8 7.9
Net Margin % TTM 13.6 4.6
ROA TTM 22.8 8.0
ROE TTM 26.5 15.8

Source: Morningstar

So, offering some of the best margins and returns (see table above) in the industry, while both insiders and hedge funds bet on its future performance, is this stock a buy?

The smart money sure thinks so.

*Includes 5780 shares jointly held with reporting person’s spouse in a revocable living trust and 820 shares held in the reporting person’s IRA.

Disclosure: Javier Hasse holds no position in any stocks mentioned

Recommended Reading:

First Financial Bancorp Director Makes a Buy

KB Home Insider Trading Activity Spikes

Yum! Brands’ Board of Directors is Eating Up Stock

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!